dalteparin has been researched along with Thrombocytopenia in 140 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 7.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 6.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| "Heparin-induced thrombocytopenia (HIT) is a serious adverse drug reaction due to its related risk of life- and limb-threatening thrombosis." | 5.72 | An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022) |
| "Rivaroxaban is an oral, direct activated Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders." | 5.35 | Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. ( Bakhos, M; Hoppensteadt, D; Iqbal, O; Jeske, WP; Maddineni, J; Messmore, HL; Prechel, M; Walenga, JM, 2008) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Dalteparin therapy was discontinued immediately, and anticoagulation was maintained with warfarin." | 5.32 | Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia. ( Kovacs, MJ; Payne, SM, 2003) |
| "To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)." | 5.15 | Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011) |
| "An uncommon case of delayed-onset dalteparin-induced skin necrosis in an 83-year-old Caucasian female patient associated with heparin-induced thrombocytopaenia (HIT) presenting on day 30 following dalteparin therapy is reported." | 3.85 | Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy. ( Gan, WK, 2017) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 3.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "Recurrent venous thromboembolism (VTE) occurs in some patients despite treatment with the standard drugs, warfarin and low-molecular-weight heparin (LMWH)." | 3.80 | Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis. ( Thachil, J, 2014) |
| " We report a case of HIT in a postoperative orthopedic 75-year-old woman in treatment with LMWH (nadroparin) complicated by pulmonary embolism and treated successfully with recombinant hirudin." | 3.76 | Heparin-induced thrombocytopenia associated with pulmonary embolism. ( Cei, M; Mumoli, N, 2010) |
| " Within the treatment group, patients who received dalteparin, enoxaparin, and UFH were significantly more likely to experience coded thrombocytopenia than those in the no treatment group." | 3.74 | Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. ( Farrelly, EM; Happe, LE; Sarnes, MW; Stanford, RH, 2008) |
| "Fixed dose 10,000 IU subcutaneous dalteparin once daily for 3 months was not associated with more complications in patients with liver or brain metastases." | 3.72 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004) |
| "Dalteparin was associated with fewer study drug-attributable HIT-related events (P = ." | 2.78 | Heparin-induced thrombocytopenia in medical surgical critical illness. ( Bersten, AD; Cook, DJ; Crowther, MA; Crozier, TM; Davies, AR; Ernest, D; Hall, RI; Heels-Ansdell, D; Marshall, JC; McIntyre, L; Mehta, S; Poirier, G; Rocha, MG; Sheppard, JI; Vlahakis, NE; Warkentin, TE; Wood, GG, 2013) |
| "Internal carotid artery stenosis was asymptomatic in 55% and symptomatic in 45%." | 2.73 | Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. ( Assadian, A; Hagmüller, GW; Hübl, W; Klingler, A; Knöbl, P; Pfaffelmeyer, N; Senekowitsch, C, 2008) |
| "Thrombocytopenia is associated with an increased risk for adverse cardiac events and bleeding in patients presenting with acute coronary syndromes (ACS) treated with unfractionated heparin (UFH)." | 2.73 | Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. ( Antman, EM; Bradner, JE; Gibson, CM; Giugliano, RP; Jang, IK; Morrow, DA; Qin, J; Scirica, B; Shui, A; Wiviott, SD; Yeh, RW, 2007) |
| "Clivarin was administered subcutaneously at a fixed daily dosage of 1750 U without any adjustment or loading dosage." | 2.71 | Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. ( Ahmad, S; Bacher, HP; Fareed, J; Hoppensteadt, DA; Lassen, MR; Leitz, H; Misselwitz, F; Walenga, JM, 2003) |
| "Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition." | 2.70 | Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 2.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| "Patients with unstable angina pectoris (UAP) or non-ST-segment elevation acute myocardial infarction (AMI) are at risk of death or recurrent ischemic events, despite receiving aspirin and unfractionated heparin (UFH)." | 2.70 | Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. ( Berkowitz, SD; Bigonzi, F; Cohen, M; Fromell, GJ; Stinnett, S, 2001) |
| "Deep vein thrombosis was assessed by routine bilateral contrast venography performed between postoperative day 5 and 9, or earlier if clinically suspected." | 2.70 | Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. ( Anderson, DR; Atkinson, KG; Barton, P; Burnstein, M; Burul, CJ; Geerts, WH; Greenwood, C; Gregoire, RC; Marshall, JC; McLeod, RS; Ross, T; Silverman, RE; Sniderman, KW; Taylor, BM; Wilson, SR, 2001) |
| " Therefore, tinzaparin administered in a dosage of 75 U anti-Xa/kg BW 12 hours before surgery is significantly more protective against proximal DVT and safer than the standard regimen of 50 U anti-Xa/kg BW started 2 hours before surgery in patients undergoing primary elective hip arthroplasty." | 2.69 | Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. ( Andersen, BS; Borris, LC; Ejstrud, P; Jensen, HP; Lassen, MR; Poulsen, KA, 2000) |
| " In standard clinical practice laboratory monitoring is not routinely performed, with drug dosing assessed by clinical inspection of the extracorporeal circuit, and the time for fistula needle sites to stop bleeding." | 2.45 | Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. ( Davenport, A, 2009) |
| " Due to a longer plasma half life together with high bioavailability and a linear dose-response relationship, the drugs can be safely and effectively administered in the hospital or ambulatory settings without the need to monitor the anticoagulant effect." | 2.42 | Clinical application of enoxaparin. ( Hofmann, T, 2004) |
| " Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs." | 2.41 | Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001) |
| " The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible." | 2.39 | Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994) |
| " Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence." | 2.39 | Contemporary use of and future roles for heparin in antithrombotic therapy. ( Gibaldi, M; Wittkowsky, AK, 1995) |
| "Heparin-induced thrombocytopenia (HIT) is a serious adverse drug reaction due to its related risk of life- and limb-threatening thrombosis." | 1.72 | An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022) |
| "Appropriate dosing of therapeutic anticoagulation during periods of thrombocytopenia remains uncertain for patients undergoing hematopoietic stem cell transplants (HSCT)." | 1.62 | Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT). ( Lam, J; Luk, SO; Tavares, E, 2021) |
| "In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL." | 1.46 | Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. ( Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J, 2017) |
| "We describe a patient with a giant thrombus on the apical wall of the left ventricle that occurred due to HIT syndrome after anterior myocardial infarction." | 1.40 | Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI. ( Balaban Kocas, B; Coskun, U; Gultekin, N; Gurmen, T; Kucukoglu, S; Sinan, UY, 2014) |
| "The pregnancy was carried to term and she delivered a healthy boy at 38 weeks of gestation." | 1.36 | Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. ( Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J, 2010) |
| "Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings." | 1.36 | Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. ( Cook, RJ; Greinacher, A; Marder, VJ; Warkentin, TE, 2010) |
| " While patients with renal impairment have a higher risk of bleeding and dosing of heparins is more difficult, there are no specific recommendations for bridging the latter patients." | 1.35 | Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. ( Hammerstingl, C; Omran, H, 2009) |
| "Rivaroxaban is an oral, direct activated Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders." | 1.35 | Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. ( Bakhos, M; Hoppensteadt, D; Iqbal, O; Jeske, WP; Maddineni, J; Messmore, HL; Prechel, M; Walenga, JM, 2008) |
| "0% for surgical patients receiving prophylactic dosing of either dalteparin or nadroparin, and 41." | 1.35 | Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. ( Egberts, TC; Huisman, A; Schobben, AF; ten Berg, MJ; van den Bemt, PM; van Solinge, WW, 2009) |
| " They analyzed rates of documented symptomatic venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) confirmed by objective methods, major bleeding, death, thrombocytopenia, and other adverse events." | 1.35 | Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. ( Fontcuberta, J; Gómez-Outes, A; Martínez-González, J; Otero-Fernández, R; Rocha, E, 2008) |
| " We analysed rates of documented symptomatic venous thromboembolism (VTE) [deep-vein thrombosis (DVT) and pulmonary embolism (PE)] confirmed by objective methods, major bleeding, death, thrombocytopaenia and other adverse events up to 6 weeks." | 1.34 | A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. ( Abad, JI; Gómez-Outes, A; Martínez-González, J; Rocha, E, 2007) |
| "Using the B16 melanoma mouse model of metastasis, subcutaneous (s." | 1.33 | Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. ( Amirkhosravi, A; Francis, JL; Linhardt, R; Mousa, SA, 2006) |
| "Leptospirosis is an acute generalized infectious disease, caused by spirochaetes, Leptospira interrogans." | 1.33 | Three cases of anicteric leptospirosis from Turkey: mild to severe complications. ( Demiroz, AP; Erdinc, FS; Hatipoglu, CA; Kinikli, S; Koruk, ST, 2006) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Dalteparin therapy was discontinued immediately, and anticoagulation was maintained with warfarin." | 1.32 | Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia. ( Kovacs, MJ; Payne, SM, 2003) |
| " Today we know that the real advantage of LMWHs is due to their high bioavailability which makes safe and reliable their subcutaneous administration without laboratory monitoring." | 1.31 | [State of the art: low-molecular-weight heparin and beyond]. ( Casali, G; Cimminiello, C; Vitali, L, 2000) |
| "The incidence of adverse events reported could be explained by the high risk profile of the study population." | 1.31 | Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. ( Borel-Derlon, A; Borg, JY; Boudignat, O; Cohen, C; Conard, J; Darmon, JY; Francoual, C; Lepercq, J; Priollet, P; Schved, JF; Tournaire, M; Yvelin, N, 2001) |
| "We report a pregnant woman with systemic lupus erythematosus and recurrent venous thromboembolism who suffered from heparin-induced thrombocytopenia type II while treated with dalteparin sodium." | 1.31 | Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. ( Geberth, M; Harenberg, J; Heene, DL; Hoffmann, U; Huhle, G, 2000) |
| "A 43-year-old white woman with adult respiratory distress syndrome developed localized dermal necrosis and thrombocytopenia secondary to subcutaneous administration of unfractionated heparin." | 1.30 | Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. ( Kollef, MH; Schaiff, RA; Tonn, ME, 1997) |
| " This agent also showed sustained activity and better bioavailability characteristics than heparin." | 1.29 | Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). ( Ahsan, A; Fareed, J; Hoppensteadt, D; Jeske, W; Lojewski, B; Walenga, JM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (17.86) | 18.2507 |
| 2000's | 63 (45.00) | 29.6817 |
| 2010's | 42 (30.00) | 24.3611 |
| 2020's | 10 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HS | 1 |
| Kim, H | 1 |
| Jeong, YJ | 1 |
| Lee, H | 1 |
| Yim, HW | 1 |
| Kim, JI | 1 |
| Moon, IS | 1 |
| Kim, JY | 1 |
| Pérez, DL | 1 |
| Peña-Romero, AG | 1 |
| Díaz-González, JM | 1 |
| Domínguez-Cherit, J | 1 |
| Righini, M | 1 |
| Galanaud, JP | 1 |
| Guenneguez, H | 1 |
| Brisot, D | 1 |
| Diard, A | 1 |
| Faisse, P | 1 |
| Barrellier, MT | 1 |
| Hamel-Desnos, C | 1 |
| Jurus, C | 1 |
| Pichot, O | 1 |
| Martin, M | 1 |
| Mazzolai, L | 1 |
| Choquenet, C | 1 |
| Accassat, S | 1 |
| Robert-Ebadi, H | 1 |
| Carrier, M | 1 |
| Le Gal, G | 1 |
| Mermilllod, B | 1 |
| Laroche, JP | 1 |
| Bounameaux, H | 1 |
| Perrier, A | 1 |
| Kahn, SR | 1 |
| Quere, I | 1 |
| ten Berg, MJ | 1 |
| van den Bemt, PM | 1 |
| Huisman, A | 1 |
| Schobben, AF | 1 |
| Egberts, TC | 1 |
| van Solinge, WW | 1 |
| Mumoli, N | 2 |
| Cei, M | 1 |
| Betrosian, AP | 1 |
| Theodossiades, G | 1 |
| Lambroulis, G | 1 |
| Kostantonis, D | 1 |
| Balla, M | 1 |
| Papanikolaou, M | 1 |
| Georgiades, G | 1 |
| Ng, HJ | 1 |
| Lee, LH | 1 |
| Stojanovich, L | 1 |
| Mikovic, Z | 1 |
| Mandic, V | 1 |
| Popovich-Kuzmanovich, D | 1 |
| Perunicic, J | 1 |
| Antonijevic, NM | 1 |
| Miljic, P | 1 |
| Djordjevic, V | 1 |
| Mikovic, D | 1 |
| Kovac, M | 1 |
| Djokic, M | 1 |
| Mrdovic, I | 1 |
| Nikolic, A | 1 |
| Vasiljevic, Z | 1 |
| Forette, B | 1 |
| Wolmark, Y | 1 |
| Barkagan, ZS | 1 |
| Luzzatto, G | 2 |
| Cordiano, I | 2 |
| Patrassi, G | 2 |
| Fabris, F | 2 |
| Szücs, G | 1 |
| Mikó, I | 1 |
| Ajzner, E | 1 |
| Póti, L | 1 |
| Szepesi, K | 1 |
| Furka, I | 1 |
| Martineau, P | 1 |
| Tawil, N | 1 |
| Breuer, HW | 1 |
| Müller, R | 1 |
| Greinacher, A | 5 |
| Cimminiello, C | 1 |
| Casali, G | 1 |
| Vitali, L | 1 |
| Vernon, SM | 1 |
| Wang, XK | 1 |
| Zhang, Y | 1 |
| Yang, CM | 1 |
| Wang, Y | 1 |
| Liu, GY | 1 |
| Lozano, R | 1 |
| Franco, ME | 1 |
| Abad, JI | 1 |
| Gómez-Outes, A | 2 |
| Martínez-González, J | 2 |
| Rocha, E | 2 |
| Otero-Fernández, R | 1 |
| Fontcuberta, J | 2 |
| Pasha, AK | 1 |
| McBane Ii, RD | 1 |
| Byrne, EM | 1 |
| Khattab, A | 1 |
| Chen, F | 1 |
| Bhagavatula, R | 1 |
| Farasatinasab, M | 1 |
| Balouchzehi, S | 1 |
| Moghaddam, OM | 1 |
| Ansarinejad, N | 1 |
| Mohammadi, M | 1 |
| Nasiripour, S | 1 |
| Shen, L | 1 |
| Liu, X | 1 |
| Chen, L | 1 |
| Gao, X | 1 |
| Xu, Y | 1 |
| Shi, D | 1 |
| Zhao, H | 1 |
| Bu, C | 1 |
| Fraser, K | 1 |
| Wang, H | 1 |
| Dordick, JS | 1 |
| Linhardt, RJ | 1 |
| Zhang, F | 1 |
| Shi, F | 1 |
| Chi, L | 1 |
| Singh, N | 1 |
| Singh Lubana, S | 1 |
| Tsai, HM | 1 |
| Lam, J | 1 |
| Tavares, E | 1 |
| Luk, SO | 1 |
| Demir, NA | 1 |
| Basturk, A | 1 |
| Ural, O | 1 |
| Sumer, S | 1 |
| Erdogdu, B | 1 |
| Kiratli, HE | 1 |
| Celik, JB | 1 |
| Koplay, M | 1 |
| Vatansev, H | 1 |
| Sadeghipour, P | 2 |
| Talasaz, AH | 2 |
| Rashidi, F | 1 |
| Sharif-Kashani, B | 1 |
| Beigmohammadi, MT | 1 |
| Farrokhpour, M | 1 |
| Sezavar, SH | 1 |
| Payandemehr, P | 1 |
| Dabbagh, A | 1 |
| Moghadam, KG | 1 |
| Jamalkhani, S | 1 |
| Khalili, H | 2 |
| Yadollahzadeh, M | 1 |
| Riahi, T | 1 |
| Rezaeifar, P | 1 |
| Tahamtan, O | 1 |
| Matin, S | 1 |
| Abedini, A | 1 |
| Lookzadeh, S | 1 |
| Rahmani, H | 1 |
| Zoghi, E | 1 |
| Mohammadi, K | 1 |
| Abri, H | 1 |
| Tabrizi, S | 1 |
| Mousavian, SM | 1 |
| Shahmirzaei, S | 1 |
| Bakhshandeh, H | 1 |
| Amin, A | 1 |
| Rafiee, F | 1 |
| Baghizadeh, E | 1 |
| Mohebbi, B | 1 |
| Parhizgar, SE | 1 |
| Aliannejad, R | 1 |
| Eslami, V | 1 |
| Kashefizadeh, A | 1 |
| Kakavand, H | 1 |
| Hosseini, SH | 1 |
| Shafaghi, S | 1 |
| Ghazi, SF | 1 |
| Najafi, A | 1 |
| Jimenez, D | 1 |
| Gupta, A | 1 |
| Madhavan, MV | 1 |
| Sethi, SS | 1 |
| Parikh, SA | 1 |
| Monreal, M | 2 |
| Hadavand, N | 1 |
| Hajighasemi, A | 1 |
| Maleki, M | 1 |
| Sadeghian, S | 1 |
| Piazza, G | 1 |
| Kirtane, AJ | 1 |
| Van Tassell, BW | 1 |
| Dobesh, PP | 1 |
| Stone, GW | 1 |
| Lip, GYH | 1 |
| Krumholz, HM | 1 |
| Goldhaber, SZ | 2 |
| Bikdeli, B | 1 |
| Haughton, B | 1 |
| Haughton, J | 1 |
| George Norman, J | 1 |
| Navid, A | 1 |
| Allport, K | 1 |
| Andrews, M | 1 |
| Mannan, K | 1 |
| Livesey, J | 1 |
| Voudris, V | 1 |
| Georgiadou, P | 1 |
| Kalogris, P | 1 |
| Kostelidou, T | 1 |
| Karabinis, A | 1 |
| Gerotziafas, G | 1 |
| Brouwers, JRBJ | 1 |
| Roeters van Lennep, JE | 1 |
| Beinema, MJ | 1 |
| Sinan, UY | 1 |
| Coskun, U | 1 |
| Balaban Kocas, B | 1 |
| Gultekin, N | 1 |
| Gurmen, T | 1 |
| Kucukoglu, S | 1 |
| Loidi Pascual, L | 1 |
| Valcayo Peñalba, A | 1 |
| Yerani Ruiz de Azúa Ciria, A | 1 |
| Yanguas Bayona, I | 1 |
| Grampp, G | 1 |
| Bonafede, M | 1 |
| Felix, T | 1 |
| Li, E | 1 |
| Malecki, M | 1 |
| Sprafka, JM | 1 |
| Dang, JD | 1 |
| Davis, LE | 1 |
| Giuliani, E | 1 |
| Melegari, G | 1 |
| Farinetti, A | 1 |
| Barbieri, A | 1 |
| Mattioli, AV | 1 |
| Campbell, PM | 1 |
| Ippoliti, C | 1 |
| Parmar, S | 1 |
| Mantha, S | 1 |
| Miao, Y | 1 |
| Wills, J | 1 |
| Parameswaran, R | 1 |
| Soff, GA | 1 |
| Walenga, JM | 4 |
| Prechel, M | 1 |
| Jeske, WP | 2 |
| Hoppensteadt, D | 2 |
| Maddineni, J | 1 |
| Iqbal, O | 1 |
| Messmore, HL | 2 |
| Bakhos, M | 1 |
| Kim, GH | 1 |
| Hahn, DK | 1 |
| Kellner, CP | 1 |
| Komotar, RJ | 1 |
| Starke, R | 1 |
| Garrett, MC | 1 |
| Yao, J | 1 |
| Cleveland, J | 1 |
| Mayer, SA | 1 |
| Connolly, ES | 1 |
| Hacobian, M | 1 |
| Shetty, R | 1 |
| Niles, CM | 1 |
| Gerhard-Herman, M | 1 |
| Vallurupalli, N | 1 |
| Baroletti, S | 1 |
| McKean, SC | 1 |
| Sonis, J | 1 |
| Parasuraman, S | 1 |
| Kosowsky, JM | 1 |
| Hammerstingl, C | 3 |
| Omran, H | 3 |
| Davenport, A | 1 |
| Petit, JS | 1 |
| Murat, O | 1 |
| Perrier, S | 1 |
| Lepouse, C | 1 |
| Jaussaud, M | 1 |
| Léon, A | 1 |
| Famularo, G | 1 |
| Gasbarrone, L | 1 |
| Minisola, G | 1 |
| De Simone, C | 1 |
| Iturbe, T | 1 |
| Español, I | 1 |
| Sánchez, A | 1 |
| Rivera, J | 1 |
| Warkentin, TE | 5 |
| Cook, RJ | 2 |
| Marder, VJ | 2 |
| Hajj-Chahine, J | 1 |
| Jayle, C | 1 |
| Tomasi, J | 1 |
| Corbi, P | 1 |
| Illes, M | 1 |
| Klaus, S | 1 |
| Simon, JC | 1 |
| Treudler, R | 1 |
| Sachithanandan, A | 1 |
| Fouda, UM | 1 |
| Sayed, AM | 1 |
| Abdou, AM | 1 |
| Ramadan, DI | 1 |
| Fouda, IM | 1 |
| Zaki, MM | 1 |
| Dashti-Khavidaki, S | 1 |
| Najmedin, F | 1 |
| Hosseinpoor, R | 1 |
| Rosenberger, LH | 1 |
| Smith, PW | 1 |
| Sawyer, RG | 1 |
| Olah, Z | 2 |
| Bereczky, Z | 1 |
| Szarvas, M | 1 |
| Boda, Z | 2 |
| Montero Ruiz, E | 1 |
| Baldominos Utrilla, G | 1 |
| López Álvarez, J | 1 |
| Santolaya Perrin, R | 1 |
| Leroux, D | 1 |
| Canépa, S | 1 |
| Viskov, C | 1 |
| Mourier, P | 1 |
| Herman, F | 1 |
| Rollin, J | 1 |
| Gruel, Y | 1 |
| Pouplard, C | 1 |
| Kerenyi, A | 1 |
| Kappelmayer, J | 1 |
| Schlammadinger, A | 1 |
| Razso, K | 1 |
| Cakmak, HA | 1 |
| Değirmenci, E | 1 |
| Ikizceli, I | 1 |
| Ibrahim, RB | 2 |
| Stroempl, LE | 1 |
| Abella, EM | 2 |
| Racine, E | 1 |
| Alikhan, R | 1 |
| Cohen, AT | 1 |
| Schneider, F | 1 |
| Assemi, P | 1 |
| Ba Faye, A | 1 |
| Sauer, B | 1 |
| Lutun, P | 1 |
| Dager, WE | 1 |
| White, RH | 1 |
| Hofmann, T | 1 |
| Herishanu, Y | 1 |
| Misgav, M | 1 |
| Kirgner, I | 1 |
| Ben-Tal, O | 1 |
| Eldor, A | 2 |
| Naparstek, E | 1 |
| DeWitt, E | 1 |
| Adams, J | 1 |
| Bostwick, C | 1 |
| O'Dell, M | 1 |
| Janssen, D | 1 |
| Peres, E | 1 |
| Dansey, R | 1 |
| Abidi, MH | 1 |
| Gumma, MM | 1 |
| Milan, N | 1 |
| Smith, DW | 1 |
| Heilbrun, LK | 1 |
| Klein, J | 1 |
| DeEugenio, DL | 1 |
| Ruggiero, NJ | 1 |
| Thomson, LJ | 1 |
| Menajovsky, LB | 1 |
| Herman, JH | 1 |
| Erdinc, FS | 1 |
| Koruk, ST | 1 |
| Hatipoglu, CA | 1 |
| Kinikli, S | 1 |
| Demiroz, AP | 1 |
| Sheppard, JA | 1 |
| Moore, JC | 1 |
| Eriksson, BI | 1 |
| Kelton, JG | 2 |
| Thamban, S | 1 |
| Opemuyi, IO | 1 |
| Swinhoe, JR | 1 |
| Cochrane, GW | 1 |
| Husedzinov, I | 1 |
| Bradic, N | 1 |
| Nikic, N | 1 |
| Barisin, S | 1 |
| Desnica, M | 1 |
| Mousa, SA | 2 |
| Linhardt, R | 1 |
| Francis, JL | 2 |
| Amirkhosravi, A | 2 |
| Fraser, GL | 1 |
| Riker, RR | 1 |
| Paar, WD | 1 |
| Happe, LE | 1 |
| Farrelly, EM | 1 |
| Stanford, RH | 1 |
| Sarnes, MW | 1 |
| Yeh, RW | 1 |
| Wiviott, SD | 1 |
| Giugliano, RP | 1 |
| Morrow, DA | 1 |
| Shui, A | 1 |
| Qin, J | 1 |
| Scirica, B | 1 |
| Bradner, JE | 1 |
| Jang, IK | 1 |
| Gibson, CM | 1 |
| Antman, EM | 1 |
| Doboszyńska, A | 1 |
| Rozek, M | 1 |
| Swietlik, E | 1 |
| Tomaszewska, I | 1 |
| Assadian, A | 1 |
| Knöbl, P | 1 |
| Hübl, W | 1 |
| Senekowitsch, C | 1 |
| Klingler, A | 1 |
| Pfaffelmeyer, N | 1 |
| Hagmüller, GW | 1 |
| Luthra, S | 1 |
| Theodore, S | 1 |
| Liava'a, M | 1 |
| Atkinson, V | 1 |
| Tatoulis, J | 1 |
| Levine, MN | 1 |
| Hirsh, J | 2 |
| Horsewood, P | 1 |
| Roberts, RS | 1 |
| Gent, M | 2 |
| Fejgin, MD | 1 |
| Lourwood, DL | 1 |
| Colwell, CW | 1 |
| Spiro, TE | 2 |
| Trowbridge, AA | 3 |
| Morris, BA | 1 |
| Kwaan, HC | 1 |
| Blaha, JD | 1 |
| Comerota, AJ | 1 |
| Skoutakis, VA | 1 |
| Grozovski, ES | 1 |
| Cohen, JD | 1 |
| Grunberg, G | 1 |
| Keslin, J | 1 |
| Gassner, S | 1 |
| Macklon, NS | 1 |
| Greer, IA | 1 |
| Reid, AW | 1 |
| Walker, ID | 1 |
| Gibaldi, M | 1 |
| Wittkowsky, AK | 1 |
| Slocum, MM | 1 |
| Adams, JG | 1 |
| Teel, R | 1 |
| Spadone, DP | 1 |
| Silver, D | 2 |
| Ganjoo, AK | 1 |
| Harloff, MG | 1 |
| Johnson, WD | 1 |
| Watters, M | 1 |
| Tonn, ME | 1 |
| Schaiff, RA | 1 |
| Kollef, MH | 1 |
| James, JK | 1 |
| Peters, FP | 1 |
| Barratt, SM | 1 |
| Ruff, SJ | 1 |
| Edwards, RC | 1 |
| Merli, G | 1 |
| Olsson, CG | 1 |
| Abildgaard, U | 1 |
| Davidson, BL | 1 |
| Elias, D | 1 |
| Grigg, A | 1 |
| Musset, D | 1 |
| Rodgers, GM | 1 |
| Yusen, RD | 1 |
| Zawilska, K | 1 |
| McLeod, RS | 1 |
| Geerts, WH | 1 |
| Sniderman, KW | 1 |
| Greenwood, C | 1 |
| Gregoire, RC | 1 |
| Taylor, BM | 1 |
| Silverman, RE | 1 |
| Atkinson, KG | 1 |
| Burnstein, M | 1 |
| Marshall, JC | 3 |
| Burul, CJ | 1 |
| Anderson, DR | 1 |
| Ross, T | 1 |
| Wilson, SR | 1 |
| Barton, P | 1 |
| Berkowitz, SD | 1 |
| Stinnett, S | 1 |
| Cohen, M | 1 |
| Fromell, GJ | 1 |
| Bigonzi, F | 1 |
| Lepercq, J | 1 |
| Conard, J | 1 |
| Borel-Derlon, A | 1 |
| Darmon, JY | 1 |
| Boudignat, O | 1 |
| Francoual, C | 1 |
| Priollet, P | 1 |
| Cohen, C | 1 |
| Yvelin, N | 1 |
| Schved, JF | 1 |
| Tournaire, M | 1 |
| Borg, JY | 1 |
| Kormanová, K | 1 |
| Krska, Z | 1 |
| Trca, S | 1 |
| Pesková, M | 1 |
| Korínková, P | 1 |
| Lindhoff-Last, E | 1 |
| Nakov, R | 2 |
| Misselwitz, F | 3 |
| Breddin, HK | 3 |
| Bauersachs, R | 1 |
| Ahmad, S | 2 |
| Haas, S | 2 |
| Hoppensteadt, DA | 2 |
| Lietz, H | 1 |
| Reid, U | 1 |
| Bender, N | 1 |
| Bacher, P | 1 |
| Gaikwad, BS | 1 |
| Fareed, J | 3 |
| Bacher, HP | 1 |
| Lassen, MR | 2 |
| Leitz, H | 1 |
| Jeske, W | 1 |
| Lojewski, B | 1 |
| Ahsan, A | 1 |
| Hach-Wunderle, V | 1 |
| Kakkar, VV | 1 |
| Riess, H | 1 |
| Koppenhagen, K | 1 |
| Tolle, A | 1 |
| Kemkes-Matthes, B | 1 |
| Gräve, M | 1 |
| Patek, F | 1 |
| Drexler, M | 1 |
| Siemens, HJ | 1 |
| Harenberg, J | 2 |
| Weidinger, G | 1 |
| Brom, J | 1 |
| Gan, WK | 1 |
| Craik, JD | 1 |
| Cobb, AG | 1 |
| Sheppard, JI | 1 |
| Heels-Ansdell, D | 3 |
| McIntyre, L | 2 |
| Rocha, MG | 2 |
| Mehta, S | 2 |
| Davies, AR | 1 |
| Bersten, AD | 1 |
| Crozier, TM | 1 |
| Ernest, D | 1 |
| Vlahakis, NE | 2 |
| Hall, RI | 1 |
| Wood, GG | 1 |
| Poirier, G | 1 |
| Crowther, MA | 1 |
| Cook, DJ | 1 |
| Thachil, J | 1 |
| Babilonia, KM | 1 |
| Golightly, LK | 1 |
| Gutman, JA | 1 |
| Hassell, KL | 1 |
| Kaiser, JN | 1 |
| Kiser, TH | 1 |
| Klem, PM | 1 |
| Trujillo, TC | 1 |
| Fowler, RA | 1 |
| Mittmann, N | 1 |
| Geerts, W | 2 |
| Gould, MK | 1 |
| Guyatt, G | 2 |
| Krahn, M | 1 |
| Finfer, S | 1 |
| Pinto, R | 1 |
| Chan, B | 1 |
| Ormanidhi, O | 1 |
| Arabi, Y | 1 |
| Qushmaq, I | 2 |
| Dodek, P | 1 |
| Hall, R | 1 |
| Ferguson, ND | 1 |
| Doig, CJ | 1 |
| Muscedere, J | 1 |
| Jacka, MJ | 1 |
| Klinger, JR | 1 |
| Vlahakis, N | 1 |
| Orford, N | 1 |
| Seppelt, I | 1 |
| Skrobik, YK | 1 |
| Sud, S | 1 |
| Cade, JF | 1 |
| Cooper, J | 1 |
| Cook, D | 2 |
| Tvito, A | 1 |
| Bakchoul, T | 1 |
| Rowe, JM | 1 |
| Ganzel, C | 1 |
| Giorgi-Pierfranceschi, M | 1 |
| Scarpioni, R | 1 |
| Croci, E | 1 |
| Dentali, F | 1 |
| Meade, M | 1 |
| Walter, S | 1 |
| Zytaruk, N | 1 |
| Crowther, M | 1 |
| Cooper, DJ | 1 |
| Vallance, S | 1 |
| Rocha, M | 1 |
| Berwanger, O | 1 |
| Smythe, MA | 1 |
| Koerber, JM | 1 |
| Liang, JJ | 1 |
| Bishu, KG | 1 |
| Anavekar, NS | 1 |
| James, S | 1 |
| Armstrong, P | 1 |
| Califf, R | 1 |
| Husted, S | 1 |
| Kontny, F | 1 |
| Niemminen, M | 1 |
| Pfisterer, M | 1 |
| Simoons, ML | 1 |
| Wallentin, L | 1 |
| Ortín, X | 1 |
| Cid, J | 1 |
| Ugarriza, A | 1 |
| Payne, SM | 1 |
| Kovacs, MJ | 1 |
| Blot, E | 1 |
| Gutman, F | 1 |
| Thannberger, A | 1 |
| Zacharski, L | 1 |
| Jiménez, JA | 1 |
| Roncales, J | 1 |
| Vilaseca, B | 1 |
| Herzog, S | 1 |
| Rath, W | 1 |
| Kuhn, W | 1 |
| Kikta, MJ | 1 |
| Keller, MP | 1 |
| Humphrey, PW | 1 |
| Altés, A | 1 |
| Martino, R | 1 |
| Gari, M | 1 |
| Cámara, ML | 1 |
| Garín, R | 1 |
| Casas, JI | 1 |
| Ramakrishna, R | 1 |
| Manoharan, A | 1 |
| Kwan, YL | 1 |
| Kyle, PW | 1 |
| Huhle, G | 1 |
| Geberth, M | 1 |
| Hoffmann, U | 1 |
| Heene, DL | 1 |
| Neuhaus, TJ | 1 |
| Goetschel, P | 1 |
| Schmugge, M | 1 |
| Leumann, E | 1 |
| Galán, AM | 1 |
| Tonda, R | 1 |
| Altisent, C | 1 |
| Maragall, S | 1 |
| Ordinas, A | 1 |
| Escolar, G | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 1 |
| McAuliffe, F | 1 |
| Byrne, B | 1 |
| Brouns, AJ | 1 |
| Jie, KS | 1 |
| Saad, RA | 1 |
| Horn, L | 1 |
| Mankad, PS | 1 |
| Amaya, M | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Borris, LC | 1 |
| Jensen, HP | 1 |
| Poulsen, KA | 1 |
| Ejstrud, P | 1 |
| Andersen, BS | 1 |
| Heit, JA | 1 |
| Elliott, CG | 1 |
| Morrey, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538] | Phase 3 | 260 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375] | 60 participants (Anticipated) | Interventional | 2021-04-20 | Not yet recruiting | |||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642] | 20 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374] | 40 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses[NCT01828697] | Phase 4 | 1,110 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied
| Intervention | cm/s (Mean) | |||
|---|---|---|---|---|
| Delta PVV from before to after Venaflow (Standing) | Delta PVV from before to after Venaflow (Supine) | delta PVV from before to after Activeca (Standing) | delta PVV from before to after Activecare (supine) | |
| 10 Healthy Patients Without THA | 127.9 | 87.1 | 32.6 | 40.5 |
| 10 Patients With THA on Post-Op Day 2 | 155.7 | 86.8 | 41.9 | 37.8 |
All-cause mortality (NCT00413374)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin 1.5 mg/kg Once Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 0 |
Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 1 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
11 reviews available for dalteparin and Thrombocytopenia
| Article | Year |
|---|---|
Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Topics: Blood Platelets; Capillary Permeability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; He | 1998 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; | 2001 |
Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Drug Approval; Enoxaparin; Europe; Humans; Practice Guid | 2019 |
Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments.
Topics: Anticoagulants; Drug Costs; Enoxaparin; Hemodiafiltration; Heparin, Low-Molecular-Weight; Humans; Re | 2009 |
Clinical application of enoxaparin.
Topics: Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Ag | 2004 |
Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Centra | 2004 |
[Thrombosis prophylaxis with heparins in intensive care patients].
Topics: Age Factors; Anticoagulants; APACHE; Critical Care; Enoxaparin; Heparin; Heparin Antagonists; Hepari | 2005 |
Gestational thrombocythaemia associated with intrauterine death: case report and a review of the literature.
Topics: Anticoagulants; Enoxaparin; Female; Fetal Death; Humans; Placenta; Placenta Diseases; Pregnancy; Pre | 2006 |
Low molecular weight heparins and their use in obstetrics and gynecology.
Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular- | 1994 |
Contemporary use of and future roles for heparin in antithrombotic therapy.
Topics: Anticoagulants; Antithrombins; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; | 1995 |
Reviparin sodium - a new low molecular weight heparin.
Topics: Absorption; Anticoagulants; Child; Drug Evaluation; Factor Xa Inhibitors; Female; Heparin, Low-Molec | 2002 |
23 trials available for dalteparin and Thrombocytopenia
| Article | Year |
|---|---|
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
[Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Heparin; Humans; Injections, Subcutaneous; Male; Nadrop | 1995 |
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca | 2006 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2011 |
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
Topics: Anticoagulants; Cross Reactions; Double-Blind Method; Enoxaparin; Fondaparinux; Hip; Humans; Immunoe | 2005 |
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heparin; Humans; Inc | 2007 |
Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Brain Ische | 2008 |
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
Topics: Confidence Intervals; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; Immunoglobulin G; Od | 1995 |
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
Topics: Aged; Alanine Transaminase; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhag | 1994 |
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administ | 2001 |
Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.
Topics: Anticoagulants; Blood Loss, Surgical; Canada; Colectomy; Double-Blind Method; Enoxaparin; Female; He | 2001 |
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
Topics: Aged; Angina, Unstable; Antifibrinolytic Agents; Double-Blind Method; Electrocardiography; Enoxapari | 2001 |
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.
Topics: Anticoagulants; Autoantibodies; Drug Administration Schedule; Female; Heparin; Heparin, Low-Molecula | 2002 |
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
Topics: Adult; Aged; Anticoagulants; Autoantibodies; Double-Blind Method; Female; Heparin; Heparin, Low-Mole | 2002 |
Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients.
Topics: Adolescent; Antibodies, Anti-Idiotypic; Antibody Specificity; Enzyme-Linked Immunosorbent Assay; Fib | 2003 |
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L | 2001 |
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Topics: Aged; Body Weight; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Heparin, Low-Molec | 2003 |
Heparin-induced thrombocytopenia in medical surgical critical illness.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Critical Illness; Dalteparin; Dose- | 2013 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Cohort Studies; Coronary Dis | 2002 |
Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Meth | 2000 |
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cause | 2000 |
106 other studies available for dalteparin and Thrombocytopenia
| Article | Year |
|---|---|
Comparative Analysis of the Suspected Heparin-Induced Thrombocytopenia Level in Korea.
Topics: Aged; Anticoagulants; Dalteparin; Drug Compounding; Drug Monitoring; Enoxaparin; Female; Humans; Inc | 2017 |
Nadroparin-induced skin necrosis: clinical manifestation of HIT-2 even in the absence of thrombocytopaenia.
Topics: Adult; Humans; Male; Nadroparin; Necrosis; Skin Diseases; Thrombocytopenia | 2016 |
Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
Topics: Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Databases, Factual; Drug Monitoring; Female | 2009 |
Heparin-induced thrombocytopenia associated with pulmonary embolism.
Topics: Aged; Antibodies; Female; Fibrinolytic Agents; Fractures, Bone; Hirudins; Humans; Nadroparin; Orthop | 2010 |
Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin.
Topics: Arthroplasty, Replacement, Hip; Disseminated Intravascular Coagulation; Female; Humans; Immunoglobul | 2003 |
Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy.
Topics: Aged; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Thrombocytopenia; T | 2003 |
Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin.
Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Autoantibodies; Dexamethasone; Dose-Resp | 2007 |
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Antibodies; Anticoagulants; Antiphospholipid Syndrome; Diagnosis, Diffe | 2008 |
[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Evaluation; Female; Heparin; Humans; Male; Middl | 1993 |
Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use.
Topics: Anticoagulants; Cross Reactions; Heparin; Humans; Immunoglobulin G; Nadroparin; Thrombocytopenia | 1996 |
Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use.
Topics: Cross Reactions; Heparin; Humans; Immunoglobulin G; Nadroparin; Thrombocytopenia; Treatment Outcome | 1995 |
Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment.
Topics: Animals; Anticoagulants; Arthroplasty, Replacement, Hip; Disease Models, Animal; Dogs; Factor Xa Inh | 1997 |
[Heparin-induced thrombocytopenia type II].
Topics: Aged; Anticoagulants; Appendectomy; Female; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; | 1999 |
[State of the art: low-molecular-weight heparin and beyond].
Topics: Anticoagulants; Biological Availability; Blood Coagulation Factors; Clinical Trials as Topic; Fibrin | 2000 |
[Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease].
Topics: Aged; Aged, 80 and over; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Female; | 2020 |
A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administ | 2007 |
Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemorrhage; | 2008 |
Heparin Skin Necrosis in Heparin-Induced Thrombocytopenia.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Injections; Necrosis; Skin Diseases; Thrombocytope | 2021 |
Rare presentation of enoxaparin-induced skin necrosis in a postoperative patient.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Necrosis; Postop | 2022 |
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pilot Projects; Pyraz | 2022 |
Heparin-induced thrombocytopenia post-cardiovascular interventional therapy: a case report.
Topics: Aged; Anticoagulants; Enoxaparin; Heparin; Humans; Male; Platelet Count; Thrombocytopenia | 2022 |
New insights into the binding of PF4 to long heparin oligosaccharides in ultralarge complexes using mass spectrometry.
Topics: Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Mass Spectrometry; | 2023 |
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.
Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Py | 2020 |
Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT).
Topics: Anticoagulants; Drug Tapering; Enoxaparin; Hematopoietic Stem Cell Transplantation; Humans; Retrospe | 2021 |
A case of Evans syndrome secondary to COVID-19.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Anticoagulants; COVID-19; Enoxaparin; Humans; Immunoglobulins, | 2021 |
Routine monitoring for heparin-induced thrombocytopenia following lower limb arthroplasty: Is it necessary? A prospective study in a UK district general hospital.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2019 |
Missed Heparin-Induced Thrombocytopenia (HIT) Diagnosis in a Patient with Acute Stent Thrombosis.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Heparin; Humans; Male; Percutaneous Coron | 2019 |
Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI.
Topics: Anticoagulants; Enoxaparin; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Thro | 2014 |
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo | 2014 |
Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.
Topics: Adverse Drug Reaction Reporting Systems; Anticoagulants; Biosimilar Pharmaceuticals; Drugs, Generic; | 2015 |
Should patients with chronic liver disease receive venous thromboembolism prophylaxis?
Topics: Anticoagulants; Blood Coagulation Disorders; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Human | 2015 |
An unusual case of enoxaparin induced thrombocytopenia in intensive care unit.
Topics: Anticoagulants; Autoantibodies; Drug Substitution; Duodenal Neoplasms; Enoxaparin; Female; Fondapari | 2015 |
Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematologic Neoplasms; Hemorrhage; Heparin, Low-Molecular- | 2017 |
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Humans; Male; Neoplasms; | 2017 |
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Topics: Analysis of Variance; Anticoagulants; Antithrombin III; Arginine; Autoantibodies; Enoxaparin; Flow C | 2008 |
The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin.
Topics: Aged; Anticoagulants; Cerebral Angiography; Cohort Studies; Enoxaparin; Female; Heparin; Humans; Mal | 2009 |
Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Case-Control Studies; Enoxaparin; Female; Follow-Up Stud | 2010 |
Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Dosage Calculations; | 2009 |
[Headaches in a 21-year-old man with Goodpasture disease].
Topics: Anti-Glomerular Basement Membrane Disease; Anticoagulants; Chondroitin Sulfates; Combined Modality T | 2009 |
Systemic bleeding in a patient with enoxaparin-induced thrombocytopenia.
Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Thrombocytop | 2009 |
[Enoxaparin-induced thrombocytopenia with associated arterial and venous thrombosis].
Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Femoral Vein; Humans; Male; Thrombocytopenia; Venous | 2011 |
Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.
Topics: Antibodies; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin; Evidence-Base | 2010 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxa | 2010 |
[Dermal necrosis as cutaneous manifestation of heparin-induced thrombocytopenia II?].
Topics: Anticoagulants; Chromosome Breakage; Chromosome Disorders; Enoxaparin; Female; Humans; Middle Aged; | 2011 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, | 2010 |
Anticoagulant utilization evaluation in a teaching hospital: a prospective study.
Topics: Adult; Aged; Anticoagulants; Cross-Sectional Studies; Drug Monitoring; Drug Utilization Review; Enox | 2010 |
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail | 2011 |
Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage.
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Aged; Anticoagulants; Arthroplasty, R | 2011 |
Coagulation: cascade!
Topics: Aged; Anticoagulants; Coumarins; Enoxaparin; Gangrene; Heparin; Humans; International Normalized Rat | 2011 |
Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
Topics: Aged; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Emergency Medical Services; Enox | 2011 |
Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.
Topics: Antibodies; Anticoagulants; Binding Sites, Antibody; Blood Platelets; Case-Control Studies; Enoxapar | 2012 |
Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antigen-Antibody Complex; Enoxaparin; Extremities; Fem | 2012 |
A giant tumor thrombi filling right ventricle in a thrombocytopenic patient with renal cell carcinoma.
Topics: Anticoagulants; Carcinoma, Renal Cell; Chest Pain; Dyspnea; Echocardiography; Enoxaparin; Heart Vent | 2012 |
Enoxaparin safety in patients with severe thrombocytopenia.
Topics: Anticoagulants; Bone Marrow Transplantation; Enoxaparin; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 2002 |
A safety analysis of thromboprophylaxis in acute medical illness.
Topics: Acute Disease; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Risk Factors; Safety; Thromb | 2003 |
[A puzzling circulatory failure after total hip replacement].
Topics: Acute Disease; Adrenal Insufficiency; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fe | 2003 |
Low-molecular-weight heparin-induced thrombocytopenia in a child.
Topics: Anticoagulants; Child; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Hirudins; Humans; Platelet | 2004 |
Gastrointestinal bleeding in an elderly patient with a recent hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Contraindications; Diagnosi | 2004 |
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.
Topics: Adult; Aged; Anticoagulants; Blood Platelets; Bone Marrow Transplantation; Cohort Studies; Enoxapari | 2005 |
Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature.
Topics: Aged; Anticoagulants; Enoxaparin; Humans; Male; Thrombocytopenia; Time Factors | 2005 |
Three cases of anicteric leptospirosis from Turkey: mild to severe complications.
Topics: Acute Kidney Injury; Acyclovir; Adult; Aged; Agglutination Tests; Ampicillin; Anti-Bacterial Agents; | 2006 |
Two cases of heparin induced thrombocytopenia type II post cardiopulmonary bypass.
Topics: Aged; Angina, Unstable; Cardiopulmonary Bypass; Enoxaparin; Female; Follow-Up Studies; Humans; Male; | 2006 |
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Cell Line, Tumor; Dose-Response R | 2006 |
Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients.
Topics: Enoxaparin; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Randomized Controlled Trials as | 2006 |
[Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Sched | 2007 |
Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
Topics: Aged; Anticoagulants; Cohort Studies; Dalteparin; Enoxaparin; Female; Fondaparinux; Health Care Cost | 2008 |
Heparin-induced thrombocytopenia in a patient with lung embolism and left-sided pneumonia: a case report.
Topics: Aged; Antibodies; Anticoagulants; Enoxaparin; Female; Humans; Platelet Factor 4; Pneumonia; Pulmonar | 2007 |
Cutaneous microangiopathic thrombosis complicated by pyoderma gangrenosum in post-cardiac surgery heparin-induced thrombocytopaenia.
Topics: Aged; Aortic Valve Stenosis; Autoantibodies; Cardiopulmonary Bypass; Enoxaparin; Female; Fibrinolyti | 2009 |
Heparin-induced thrombocytopenia and paradoxical venous thromboses.
Topics: Aged; Axillary Vein; Coronary Disease; Diabetes Mellitus, Type 2; Enoxaparin; Female; Femoral Vein; | 1993 |
Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Enoxaparin; Female; Fetal Death; Heparin; Huma | 1995 |
Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome.
Topics: Aged; Antibodies; Anticoagulants; Blood Platelets; Enoxaparin; Evaluation Studies as Topic; Female; | 1996 |
Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin.
Topics: Aged; Anticoagulants; Cardiopulmonary Bypass; Coronary Disease; Enoxaparin; Heparin; Humans; Male; T | 1996 |
Enoxaparin (Clexane) HITS.
Topics: Antibodies; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggr | 1996 |
Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies.
Topics: Adult; Antibodies; Anticoagulants; Cross Reactions; Drug Eruptions; Enoxaparin; Female; Heparin; Hum | 1997 |
Enoxaparin (Clexane) HITS.
Topics: Anticoagulants; Blood Loss, Surgical; Enoxaparin; Female; Humans; Knee Prosthesis; Middle Aged; Post | 1996 |
Treatment of heparin-induced thrombocytopenia.
Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Enoxaparin; Heparin; Heparinoids; Heparitin | 1997 |
Heparin-induced thrombocytopenia presenting after the cessation of low molecular weight heparin prophylaxis with enoxaparin.
Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Enoxaparin; Female; Hepar | 2000 |
Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Topics: Adult; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Infant, Newborn; Intracrania | 2001 |
[Heparin-induced thrombocytopenia in patients and prevention with low molecular weight heparin].
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; | 2001 |
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).
Topics: Animals; Bleeding Time; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Molecular Weight; P | 1993 |
Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy.
Topics: Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Diagnosis, Differenti | 2017 |
Heparin-induced thrombocytopenia following hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; Female; | 2013 |
Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Topics: Adult; Anticoagulants; Dalteparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Injections, | 2014 |
Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.
Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Dalteparin; Female; Fibrinolytic Agents; Hospital | 2014 |
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Topics: Anticoagulants; Cost-Benefit Analysis; Critical Illness; Dalteparin; Female; Health Expenditures; He | 2014 |
Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
Topics: Aged, 80 and over; Antibodies; Anticoagulants; Blood Platelets; Dalteparin; Female; Fondaparinux; Hi | 2015 |
Argatroban for Treatment of Heparin-Induced Thrombocytopenia and Thrombosis in a Patient with Multiple Myeloma Undergoing Hemodialysis.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Dalteparin; Female; Humans; Multiple Mye | 2016 |
Dalteparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Heparin; Humans; Thrombocytopenia; Venous Thrombosis | 2011 |
42-year-old man with hemoptysis, dyspnea, and orthopnea.
Topics: Adult; Anticoagulants; Dalteparin; Diagnosis, Differential; Dyspnea; Hemoptysis; Humans; Male; Mitra | 2012 |
[Dalteparin induced thrombocytopenia. Study of a case].
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Humans; Thrombocytopenia | 2002 |
Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia.
Topics: Antibodies; Dalteparin; Humans; Male; Middle Aged; Skin; Skin Diseases; Thrombocytopenia; Warfarin | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Bias; Dalteparin; Humans; International Normali | 2003 |
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor | 2004 |
[Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
Topics: Adult; Anticoagulants; Cesarean Section; Chondroitin Sulfates; Cross Reactions; Dalteparin; Dermatan | 1995 |
Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies; Chondroitin Sulfates; Dalteparin; Dermatan S | 1993 |
Heparin-induced thrombocytopenia and heart operation: management with tedelparin.
Topics: Cardiopulmonary Bypass; Dalteparin; Female; Heart Valve Prosthesis; Heparin; Humans; Middle Aged; Mi | 1995 |
Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
Topics: Adult; Aged; Aged, 80 and over; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Interaction | 1995 |
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.
Topics: Adult; Anticoagulants; Antithrombins; Dalteparin; Female; Heparin; Hirudin Therapy; Humans; Lupus Er | 2000 |
Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.
Topics: Adolescent; Anticoagulants; Child; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinat | 2000 |
Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Platelets; Coagulants; Dalteparin; Factor VII; Facto | 2001 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
[Erythema after subcutaneous heparin treatment].
Topics: Adult; Anticoagulants; Female; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Platelet Count; | 2015 |
Management dilemma of cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Topics: Aged; Axillary Vein; Cardiopulmonary Bypass; Female; Fibrinolytic Agents; Heart Atria; Heart Neoplas | 2002 |
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Topics: Animals; Endothelium, Vascular; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Lipoprot | 2003 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
Ardeparin and danaparoid for prevention of deep vein thrombosis.
Topics: Abdomen; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chondroiti | 1997 |